Author

H. Tian

Institution: Johnson & Johnson (United States)

Observed institution: Johnson & Johnson (United States)

OpenAlex ID: A5121328829

300eP Model-informed drug development (MIDD) to support dose selection of pasritamig, a KLK2xCD3 bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC)

2025 · E. Calvo, H. T'Jollyn, et al. · Immuno-Oncology Technology

Works count: 1

Citation count:

H-index:

I10-index: